The central problem is technical. Unlike protein-coding genes, lncRNAs show low sequence conservation across species, are expressed at low levels, and often have complex structures that make them hard to detect, quantify, and manipulate. Traditional RNA interference, the workhorse of gene-silencing experiments for two decades, has been applied to only a small number of systematic lncRNA screens because of high costs, incomplete annotation, and limited scalability. CRISPR-based approaches such as CRISPR knockout, CRISPR interference, and CRISPR activation have filled some of the gap, but they share a fundamental limitation: they act on DNA. Because many lncRNAs are produced from overlapping or repetitive genomic regions, a single guide RNA aimed at the genome often fails to abolish the transcript. Complete knockout typically requires dual guide RNAs to create large deletions, or laborious monoclonal screening to generate homozygous knockout lines, all of which is inefficient, prone to off-target effects, and risks accidentally disrupting neighboring protein-coding genes.

To get around these obstacles, Neville E. Sanjana’s team developed CaRPool-seq, short for Cas13 RNA Perturb-seq, a transcriptome-scale screening platform built on CRISPR-Cas13. Unlike Cas9, which cuts DNA, Cas13 is an RNA-guided, RNA-targeting nuclease. Guide RNAs designed against a given transcript bind and silence it directly at the RNA level, leaving the underlying genome untouched. That single design change minimizes nonspecific DNA editing, reduces off-target interference, and makes it possible to knock down lncRNAs precisely and in parallel across thousands of targets at once. In effect, the platform converts the entire transcriptome into a druggable target space for functional screening.

The scale of the experiment is what makes it remarkable. The researchers mined lncRNA expression data from seven human organs sampled across 26 developmental stages, spanning everything from four weeks of gestation to late adulthood, and used that information to build a guide RNA library targeting 6,199 lncRNAs alongside 4,390 protein-coding genes. The library, comprising roughly 75,000 guide RNAs, was delivered into five human cell lines, HAP1, HEK293T, K562, MDA-MB-231, and THP1, using lentiviral vectors. The team then tracked the abundance of each guide RNA at days zero, seven, and fourteen after delivery. The logic is elegantly simple: if depleting a particular lncRNA harms the cell, cells carrying guides against that transcript will underperform, and those guides will become depleted from the population over time. A significant drop in guide abundance therefore signals that the targeted RNA is doing something the cell cannot live without.

The screen identified 778 lncRNAs that are essential for survival in at least one cell line. Of those, 46, including the well-known nuclear speckle transcript MALAT1 and the MIR17HG locus, proved essential across all five cell lines, a universality that suggests deeply conserved, core cellular functions. These universally essential lncRNAs shared several telling characteristics: they tended to be highly expressed, their function appeared conserved, and structurally they were predominantly antisense or bidirectional transcripts rather than isolated intergenic ones. That architectural bias hints that genomic context, the way a lncRNA sits relative to its neighbors on the DNA, may shape what these molecules do. Perhaps most intriguingly, most essential lncRNAs did not show significant co-expression with adjacent protein-coding genes, arguing that they act as functionally independent entities rather than byproducts of nearby gene activity, potentially operating through long-range or cross-regulatory mechanisms.

Comparing the essential lncRNAs with essential protein-coding genes revealed further surprises. Both classes were enriched among the guide RNAs showing the strongest depletion, confirming that the screen was genuinely detecting genes the cells depend on. But unlike essential protein-coding genes, essential lncRNAs tended to exert their effects at relatively low expression levels, meaning that scarcity does not equal insignificance in the RNA world. Functionally, when the researchers depleted these transcripts, cells primarily responded by undergoing apoptosis and losing normal cell-cycle progression, two hallmarks of a cell losing control of its most basic survival programs.

To move beyond survival phenotypes and understand what these lncRNAs are actually doing, the team integrated CaRPool-seq with single-cell transcriptome analysis, allowing them to read out the full gene-expression consequences of each knockdown in individual cells. This revealed that loss of essential lncRNAs impairs cell-cycle progression and promotes programmed cell death. Gene set enrichment analysis pointed to strong associations with the major proliferation-controlling pathways, including MYC, mTOR, p53, E2F, and the G2M checkpoint, and crucially, these effects were independent of changes in neighboring protein-coding genes. The essential lncRNAs also showed dynamic expression during development: they were highly expressed in early embryogenesis, downregulated as development proceeded, and enriched in proliferative tissues such as brain, heart, liver, and kidney. Their expression rose sharply during early stages of cell proliferation and declined later, consistent with a role in shepherding cells through growth phases.

The clinical implications emerged when the team turned to cancer. Analyzing roughly 9,000 tumor transcriptomes, they found that essential lncRNAs display aberrant expression signatures across cancers, co-express with known oncogenic drivers, and correlate with patient survival outcomes. Notably, essential lncRNAs showed greater expression variability in cancer cells than their non-essential counterparts, a pattern that underscores their potential role in tumor heterogeneity, the diversity of cell states within a tumor that makes many cancers so hard to treat. Because lncRNAs are often expressed in a tissue- and disease-specific manner, they are attractive candidates for biomarkers and for therapies that could, in principle, target cancer cells while sparing healthy tissue.

The study, published as an editorial commentary in Advanced Biotechnology, marks a significant advance in lncRNA biology by demonstrating that transcriptome-scale, RNA-targeting CRISPR-Cas13 screens can identify essential non-coding transcripts with high precision and scalability. The approach is not limited to lncRNAs; it can in principle be extended to other non-coding RNA classes, including microRNAs and circular RNAs, opening a systematic path to functional annotation of the entire non-coding transcriptome. Still, the field faces real challenges. The structural complexity of lncRNAs complicates guide RNA design, current libraries do not yet cover the full transcriptome, and downstream validation in disease-relevant models remains necessary before screening hits can be translated into the clinic.

Looking ahead, the authors argue that progress will depend on more sophisticated bioinformatics tools, potentially combining artificial intelligence with RNA structural modeling, to optimize guide design, reduce off-target effects, and push screens to even greater scale. If those improvements materialize, RNA-targeting CRISPR platforms like CaRPool-seq could accelerate the translation of lncRNA research into precision diagnostics and therapies, finally giving the dark matter of the genome the functional map it has long lacked.

Subject of Research: Transcriptome-scale CRISPR-Cas13 screening to identify essential long non-coding RNAs in human cells

Article Title: Uncovering essential lncRNAs through transcriptome-scale CRISPR-Cas13 screening

Article References: Uncovering essential lncRNAs through transcriptome-scale CRISPR-Cas13 screening. (n.d.). https://doi.org/10.1007/s44307-025-00082-8

Image Credits: AI Generated

DOI: 10.1007/s44307-025-00082-8

Keywords: lncRNA, CRISPR-Cas13, CaRPool-seq, non-coding RNA, functional genomics, single-cell transcriptomics, RNA targeting, gene screening, apoptosis, cell cycle, cancer biomarkers, precision medicine

RNA-targeting CRISPR systems, most notably those built around the Cas13 family of enzymes, have rapidly become a mainstay of functional genomics. By programming a guide RNA, researchers can direct Cas13 to bind and cleave virtually any transcript of interest, suppressing gene expression without permanently editing the genome. This makes the approach attractive both as a research tool and, increasingly, as the basis for therapeutic concepts in which a harmful RNA molecule is selectively degraded while the underlying DNA remains untouched.

Assessing whether these systems actually work, however, depends on accurate measurement of the target RNA. RT–qPCR has been the default method for decades: the enzyme reverse transcriptase copies RNA into complementary DNA, and the qPCR step then amplifies and quantifies that cDNA. If the amount of a specific transcript drops after CRISPR treatment, the resulting fluorescence curve shifts, and software converts the shift into a fold-change estimate. The technique is sensitive, cheap, and deeply embedded in laboratory practice, which is precisely why an artifact embedded within it has such broad consequences.

The new analysis shows that the very reagents used to deliver RNA-targeting CRISPR can interfere with the reverse transcription step itself. Guide RNAs, Cas13 proteins, and their associated components persist in cell lysates and can inhibit, compete with, or otherwise perturb the conversion of the target transcript into cDNA. When less cDNA is generated from the treated sample than from the untreated control, the qPCR readout interprets this as a loss of the transcript, even though the RNA molecule itself may still be present at nearly normal levels. The result is an apparent knockdown that is partly, or in some cases largely, an artifact of the measurement rather than a true biological effect.

According to the authors, this interference is pervasive across common experimental configurations, affecting multiple guide designs, delivery formats, and target transcripts. The magnitude of the distortion varies, but the direction is consistent: toward overestimating depletion. Because many published benchmarks of RNA-targeting CRISPR have relied on RT–qPCR as the primary or sole quantitative endpoint, the study suggests that a substantial body of reported knockdown efficiencies may need to be revisited. Some targets reported as strongly suppressed by Cas13 systems may in fact be only modestly affected.

The implications extend well beyond academic reproducibility. RNA-targeting CRISPR therapeutics are being developed for conditions ranging from viral infections to toxic-gene diseases, where the clinical promise rests on the ability to degrade a pathogenic transcript. If preclinical assessment of these candidates has depended on RT–qPCR values inflated by reagent interference, developers may have overestimated how much of the target RNA is actually removed in treated tissues. That, in turn, could alter dose predictions, safety calculations, and expectations about the biological consequences of treatment.

Importantly, the researchers did not conclude that RNA-targeting CRISPR fails to work. Direct evidence from orthogonal methods indicates that Cas13 and related enzymes genuinely cleave their targets, and many well-controlled studies have documented real knockdown. The problem is one of calibration: the field’s most convenient measurement tool has been quietly distorting the scale of the effect. The authors emphasize that distinguishing true RNA depletion from measurement artifact is essential for building an accurate picture of what these systems can achieve in practice.

The study also outlines strategies for mitigating the artifact. These include purifying RNA more stringently before reverse transcription to remove interfering components, introducing exogenous controls that can reveal inhibition of the RT step, normalizing measurements against templates added after the CRISPR reaction, and cross-checking knockdown with methods that bypass reverse transcription altogether, such as RNA sequencing, northern blotting, or amplification-free detection approaches. By triangulating across methods that are susceptible to different failure modes, laboratories can arrive at estimates of knockdown that better reflect biology.

For the broader genomics community, the findings serve as a reminder that measurement artifacts can propagate invisibly through entire literatures. RT–qPCR earned its reputation through sensitivity and convenience, but those virtues depend on assumptions that new experimental workflows can quietly violate. As RNA-targeting CRISPR matures from an exciting technique into a platform for therapeutics, the study argues, the field must apply the same scrutiny to its measurements as it does to its enzymes—because an inflated number in a notebook today can become an inflated expectation in a clinic tomorrow.

To appreciate why the artifact has gone unnoticed for so long, it helps to consider the mechanics of a typical RT–qPCR workflow. In a standard experiment, cells are lysed shortly after delivery of the CRISPR machinery, and total RNA is extracted from the resulting lysate. The assumption underlying this practice is that the extraction step cleanly separates nucleic acids from everything else in the cell, delivering a purified RNA sample whose composition reflects the biology of the treated cells. The new findings show that this assumption is fragile: components introduced by the experiment itself can carry over into the reverse transcription reaction, where they exert effects that are indistinguishable, in the final fluorescence trace, from genuine transcript depletion.

Reverse transcriptase is an enzyme with well-characterized vulnerabilities. It is sensitive to reaction conditions, can be impeded by structured or highly abundant RNA species, and is readily affected by proteins, detergents, and small molecules that contaminate an RNA preparation. Guide RNAs are a particularly interesting class of potential interferent because they are deliberately introduced at high copy numbers and are chemically identical in kind to the transcripts being measured. A surplus of exogenous RNA in a lysate can alter the kinetics with which reverse transcriptase encounters and copies any given template, shifting the apparent abundance of a target even when its true concentration has not changed.

Quantitative PCR also depends on internal logic that can be quietly subverted. The technique is relative by design: a treated sample is always compared against a control, and the fold-change is computed from the difference in amplification behavior between the two. This comparative structure is powerful, but it means that any perturbation applied asymmetrically—for example, an inhibitor present only in treated samples—translates directly into an apparent change in abundance. The artifact therefore exploits the comparative nature of qPCR rather than any flaw in the chemistry of amplification itself, which helps explain why routine quality checks on the PCR step fail to flag the problem.

Historical precedent offers some comfort to those worried about the durability of the affected literature. Measurement artifacts have repeatedly reshaped molecular biology, from early issues with RNA interference reagents triggering off-target innate immune responses to the well-documented problems of antibody specificity and cell-line misidentification. In each case, the field eventually converged on validation standards—replication with independent reagents, orthogonal readouts, and reporting guidelines—that made the artifacts visible and controllable. The present study can be read as a step in that same tradition, converting a vague suspicion that something is off into a mechanistic account with concrete remedies.

The remedies themselves deserve attention because they vary in cost and rigor. Adding a spike-in control—a known quantity of exogenous RNA introduced at the lysis stage—allows a laboratory to detect whether reverse transcription is being inhibited, since inhibition will suppress the signal from the spike-in as well as from endogenous transcripts. This approach is inexpensive and can be retrofitted into existing workflows with minimal disruption. More definitive, though more demanding, is to move the measurement entirely away from reverse transcription, relying on methods that interrogate RNA directly. Each strategy intercepts the artifact at a different point, which is why the authors advocate combining them rather than treating any single fix as sufficient.

For journals and reviewers, the findings raise practical questions about editorial standards. Knockdown efficiency numbers appear in abstracts, grant applications, and regulatory filings, yet the measurement methods behind them are rarely scrutinized with the intensity applied to, say, statistical analyses. The study suggests that reporting the composition of delivery reagents, the presence of spike-in controls, and the use of at least one reverse-transcription-independent validation method should become standard practice for claims of RNA depletion. Such requirements would not eliminate the convenience of RT–qPCR but would force claims built upon it to be explicitly qualified.

There is also a conceptual lesson about the difference between a tool’s reliability and the reliability of conclusions drawn from it. RT–qPCR remains an excellent technique within its validated envelope; the artifact arises when experimental contexts push it outside that envelope in ways no individual assay reveals. This pattern—sound method, invalidated conclusion—is among the hardest failure modes in science to police, because each individual experiment looks internally consistent. Only when someone systematically varies the conditions across many experiments does the bias emerge, which is precisely the kind of cross-experimental analysis the new study performs.

Finally, the work underscores why investments in measurement science pay outsized dividends. Enzymes like Cas13 attract headlines and funding because they are novel and mechanistically elegant, yet the value of the entire enterprise rests on quantification. A modest program to characterize, standardize, and stress-test the assays used to evaluate a technology can shape the field as profoundly as improvements to the technology itself. In this case, a careful audit of a routine laboratory step may end up recalibrating a decade of reported results and sharpening the trajectory of an emerging therapeutic platform.

Subject of Research: A reverse transcription qPCR artifact that overestimates RNA knockdown by RNA-targeting CRISPR systems

Article Title: A pervasive RT–qPCR artifact inflates RNA knockdown by RNA-targeting CRISPR

Article References: Watkins, L., Zhu, A., & Wu, B. (2026). A pervasive RT–qPCR artifact inflates RNA knockdown by RNA-targeting CRISPR. Nature Biotechnology. https://doi.org/10.1038/s41587-026-03291-1

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03291-1

Keywords: RT-qPCR, RNA knockdown, CRISPR, Cas13, RNA-targeting, measurement artifact, reverse transcription, gene expression, functional genomics, RNA therapeutics, Nature Biotechnology, pervasive